An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes
复制标题
DOI：
10.1007/s00415-005-0882-0
复制
发表时间：
2006-01-01
影响因子：
6
通讯作者：
Smitt, PS
中科院分区：
文献类型：
--
作者：
Shams'ili, S;de Beukelaar, J;Smitt, PS
抗CD 20单克隆抗体（利妥昔单抗）有效地用于治疗B细胞淋巴瘤。最近的文献报道表明，抗体相关的自身免疫性疾病可能对利妥昔单抗有反应。因此，我们治疗了9例抗Hu或抗Yo相关的副肿瘤性神经综合征（PNS）患者，最多每月4次静脉输注利妥昔单抗（375 mg/m2）。在这项利妥昔单抗非对照、非盲试验中，3名患者的兰金量表（RS）改善≥ 1分。1例边缘系统脑炎患者病情明显好转（RS从5分降至1分）。利妥昔单抗在自身抗体相关PNS中的进一步研究是必要的。
Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated paraneoplastic neurological syndromes (PNS) with a maximum of four monthly IV infusions of rituximab (375mg/m(2)). In this uncontrolled, unblinded trial of rituximab, three patients improved >= 1 point on the Rankin Scale (RS). One patient with limbic encephalitis improved dramatically (RS from 5 to 1). Further studies of rituximab in autoantibody associated PNS are warranted.